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Abstract: This study investigated the oncologic impact of loss of
SMAD4 expression in resected left-sided pancreatic cancer and its
correlation with tumor metabolism.
From 2005 to 2011, the medical records of patients who underwent
radical distal pancreatectomy for resectable pancreatic cancer were
retrospectively reviewed. Formalin-fixed, paraffin embedded tissue
from 32 patients was investigated. Clinicopathological characteristics,
immunostaining of SMAD4, and positron emission tomography-based
parameters were analyzed in relation to oncologic outcomes.
Thirteen patients were women and 19 were men, with a mean age of
63 9.4 years. Mean resected tumor size was 3.3 1.5 cm. Ten patients
(31.3%) showed loss of SMAD4 expression. No significant clinico-
pathological differences were noted according to SMAD4 expression
(P> 0.05); however, patients with loss of SMAD4 showed significantly
poorer disease-free survival (mean 57.4 months vs mean 17.6 months,
P¼ 0.006). As a cut-off value, a SUVmax of 4.5 was found to be
predictive of loss of SMAD4 with a sensitivity of 75% and a specificity
of 84.6%. In logistic regression analysis, SUVmax>4.5 was found to
infer a 16-fold higher risk for loss of SMAD4 in resected left-sided
pancreatic cancers (Exp[b]¼ 16.5, P¼ 0.012, 95% confidence interval:
1.832–148.606).
Loss of SMAD4 is associated with poor oncologic outcomes.
SUVmax can predict loss of SMAD4 in resected left-sided pancreatic
cancer. SUVmax may be a clinical biomarker for detecting loss of
SMAD4 expression and predicting early systemic metastasis.
(Medicine 95(17):e3452)D, Jiae Park, MD im, MD, PhD,
, PhD, and Woo Jung Lee, MD, PhD
PET-CT = positron emission tomography/positron emission
tomography-computed tomography, ROC = receiver operating
characteristic, SUVmax = maximum standardized uptake value,
TLG = total lesion glycolysis, VOI = volume of interest.
INTRODUCTION
P ancreatic cancer results from an accumulation of somaticmutations in multiple genes, including K-ras, p16, p53, and
SMAD4.1 SMAD4 is a major tumor-suppressing gene involved
in the development of pancreatic cancer. Inactivation of SMAD4
occurs more frequently in pancreatic cancer than in other
cancers harboring K-ras, p16, and p53 mutations.2
SMAD4 is suggested to be a useful prognostic marker in
pancreatic cancer. SMAD4 deficiency rapidly promotes K-ras-
initiated neoplasms3 and enhances metastasis more frequently
than that which is seen in Smad4-intact tumors.4 Iacobuzio-
Donahue et al5 performed autopsies on 76 patients with pan-
creatic cancer and found that SMAD4-negative status was
highly correlated with widespread metastasis. Thus, preopera-
tive determination of SMAD4 status could be of use in stratify-
ing patients for appropriate treatment.
Several studies support the potential role of SMAD4 in the
clinical oncology of pancreatic cancer.6–8 Others, however,
report contradictory results, showing loss of SMAD4 expression
to be significantly associated with better survival after resection:
Biankin et al9 evaluated deleted in pancreatic cancer 4 (DPC4)/
SMAD4 expression in relation to pancreatic cancer outcomes.
They found that loss of DPC4/Smad4 expression was correlated
with resectability and improved survival after resection.Winter et
al10 found regional lymph node metastasis to be the only factor
predictive of distant metastasis; SMAD4was not associated with
recurrence or early cancer-related death. These results highlight
the continuing controversy regarding the clinical application of
SMAD4 in pancreatic cancer treatment.
In this study, we evaluated the oncologic impact of
SMAD4 expression on resected pancreatic cancer. To exclude
potential bias from other periampullary cancers, we focused
only on left-sided pancreatic cancer. Additionally, we assessed
SMAD4 expression in relation to 18-fluoro-deoxyglucose
(18FDG) positron emission tomography/positron emission tom-
ography-computed tomography (PET/PET-CT) to determine
the clinical implications of SMAD4 expression in the clinical
oncology of resectable pancreatic cancer.
METHODS
Review of Medical Records
5 to December 2011, 50 patients at our
ical distal pancreatosplenectomy for left-
. Ductal adenocarcinoma was confirmed
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FIGURE 1. Patient enrolment, schematic illustration showing
patient enrollment in this study. Among 55 patients who under-
Kang et alin all patients. Fifteen patients with preoperative neoadjuvant
treatment and 9 without available paraffin-embedded tissue
blocks were excluded (Figure 1). We reviewed the medical
records of 32 patients who underwent resection for national
comprehensive cancer network guideline-based resectable left-
sided pancreatic cancer.11 Clinicopathological characteristics,
such as age, gender, clinical presentation, tumor size, histo-
pathological features, and follow-up data, were reviewed and
recorded. The Institutional Review Board of Yonsei University
College of Medicine approved this study protocol.
PET-CT Analysis
In the present study, PET-CT imaging was conducted as
follows: 18F-FDG PET scans were obtained on a dedicated PET-
CT scanner (Discovery STe, GE Healthcare). Patients were
instructed to fast for at least 6 hours before the scans, and a
glucose level of140.0mg/dL was administered to all patients.
Scans were started at 60minutes after intravenous injection of
5.5MBq/kg of 18F-FDG. CT scans were initially performed at
30mA and 130 kVp without contrast-enhancement for attenu-
ation correction. Then, PET scans were performed with a 3min/
bed position in a 3-dimensional mode. PET/CT images were
reconstructed using an iterative algorithm, ordered subset
went resection of left-sided pancreatic cancer, 32 patients were
selected.expectation maximization with attenuation correction. 18F-
FDG PET/CT images were reviewed and analyzed by 2 nuclear
medicine physicians. Maximum standardized uptake value
FIGURE 2. Expression of SMAD4 in resected left-sided pancreatic cance
immunostaining results, patients were divided into 2 groups: SMAD4
2 | www.md-journal.com(SUVmax), metabolic tumor volume (MTV2.5), and total lesion
glycolysis (TLG) on PET images were measured using com-
mercially available imaging software (MIM-6.4, MIM software
Inc., Cleveland, OH, USA)14. Each tumor was examined with a
spherical volume of interest (VOI) that included the entire
lesion in the axial, sagittal, and coronal planes. Using CT
images, 18F-FDG uptake of normal organs, such as the bowel,
stomach, and liver, was not included in the VOI. The SUVmax of
the VOI was calculated as (decay-corrected activity/tissue
volume)/(injected dose/body weight). MTV2.5 was defined as
a total tumor volume with SUV 2.5. MTV and mean SUVof
the VOI were automatically calculated. TLG was calculated as
(mean SUV)T (MTV). In patients with SUVmax <2.5, MTV2.5
and TLG were not measured. Metabolic volume was calculated
according to the steepest gradient of FDG uptake, the so-called
PET-Edge calculation (MTVEdge).
15 For edge detection, the
cursor was dragged out over the lesion until 3 orthogonal
guiding lines covered the boundaries of the lesion. Then, the
edge detection software automatically calculated metabolic
tumor volume in 3 dimensions.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were
deparaffinized and rehydrated for antigen retrieval. Immuno-
histochemical analysis used prediluted anti-Smad4 (Abcam,
#ab13786) according to the manufacturer’s instructions. All
slides were reviewed by 2 pathologists from the Korean CFC, a
domestic pathology laboratory company specializing in immu-
nohistochemistry (http://www.koreacfc.com/intro/intro01.asp),
who were blinded to the oncologic outcomes and values of the
PET-based parameters. SMAD4 staining intensity was scored as
0 for loss of expression and 1 for intact expression (Figure 2).
Statistical Analysis
Statistical analysis was performed using SPSS II software
(IBM Corporation, Chicago, IL). Continuous variables were
expressed as a mean  standard deviation, and categorical
variables were expressed as a frequency (percent). Receiver
operating characteristic (ROC) curves were used to determine
optimal cutoff values for PET-based parameters in order to
predict SMAD4 expression. Univariate analysis was performed
using Chi-square with Fisher’s exact test, and Mann–Whitney’s
U test was applied for statistical assessment of the associations
between clinicopathological characteristics and PET-based
Medicine  Volume 95, Number 17, April 2016parameters. Odds ratios and their 95% confidence intervals
were estimated using logistic regression analysis. Disease-
specific survival was calculated from the time of diagnosis to
r. According to SMAD4 expression on pathological examination of
-loss (A) and SMAD4-intact (B).
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death or last follow-up day, and disease-free survival was
calculated from the time of surgery to disease recurrence (local,
systemic, both). In particular, the period of time from surgery to
systemic recurrence, as initial recurrence, was defined as
systemic metastasis-free survival. Survival was analyzed by
the Kaplan–Meier method. Survival outcomes were compared
by the log-rank test, and Cox’s proportional hazards model was
applied for multivariate analysis. All P-values <0.05 were
considered statistically significant.
RESULTS
Patient Demographics
All patients underwent distal pancreatosplenectomy; 13
were women and 19 were men, with a mean age of 63 9 years.
Sixteen patients had clinical symptoms. Abdominal pain and
discomfort was the most common symptom, which was
reported in 16 patients. Indigestion was noted in 5 patients,
weight loss in 2 patients, and anorexia/nausea in 1 patient. Of
the tumors, 25 were located in the pancreatic body, 5 in the tail,
and 2 in the body and tail. Mean tumor size was 3.3 1.5 cm in
the maximal diameter. Five patients required a combined
resection, such as that of the adrenal gland, a left nephrectomy,
or segmental resection of the transverse colon. Stage I was noted
in 1 patient, Stage IIA in 13, Stage IIB in 16, and Stage III in 2.
Margin-negative resection (R0) was reported in 27 patients
(84.4%). Post-adjuvant chemotherapy was administered to
23 patients (71.9%). During the follow-up period (mean
37.2 months [range, 1.5–96.97]), the 5-year disease-specific
survival was 38.9% (17 cancer-related mortalities among 32
patients), and disease-free survival was 43.4% (21 postoperative
cancer recurrences among 32 patients at 5 years after surgery).
SMAD4 Expression in Resected Left-Sided
Pancreatic Cancer
Among 32 patients who underwent radical pancreatectomy
Medicine  Volume 95, Number 17, April 2016for left-sided pancreatic cancer, 22 (68.8%) showed intact
SMAD4 expression, and the other 10 (31.3%) had no expression
of SMAD4 (Figure 2A and B).
TABLE 1. Clinicopathological Characteristics According to SMAD
Lo
Gender Female/Male
Age (years) 6
Symptoms No/Yes
Smoker No/Yes
CA 19–9 32
Tumor Size
Combined Resection No/Yes
pT-stage T1/T2/T3/T4 
pN-stage N0/N1
LNR 0
Differentiation WD/MD/PD/UN
LVI No/Yes
PNI No/Yes
R-status R0/R1/R2
LNR¼ lymph node ratio; LVI¼ lymphovascular invasion; MD¼mo
PNI¼ perineural invasion; UN¼ un-differentiation; WD¼well differentiat
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Oncologic Impact of SMAD4 Expression in
Resected Left-Sided Pancreatic Cancer
No significant differences were observed in clinicopatho-
logical characteristics according to SMAD4 expression in
patients with resected left-side pancreatic cancer (Table 1).
However, pancreatic cancer patients with intact SMAD4
expression showed significantly longer disease-free survival,
compared to patients without SMAD4 expression (mean 57.4
months [95% CI: 41.4–73.3] vs mean 17.6 months [95% CI:
6.3–28.9], P¼ 0.006, Figure 3).
Values of PET-Based Parameters in Predicting
Loss of SMAD4 Expression in Resected Left-Sided
Pancreatic Cancer
We noted that resected left-sided pancreatic cancers with
intact SMAD4 expression had relatively lower values for PET-
based parameters (Figure 4). Among PET-based parameters,
only SUVmax was statistically different according to SMAD4
expression in resected left-sided pancreatic cancer (5.4 2.2 vs
3.6 1.7, P¼ 0.025, Table 2).
According to ROC analysis, a SUVmax of 4.5 was
suggested as a cutoff value for predicting loss of SMAD4 in
resected left-sided pancreatic cancer, with a sensitivity of 75%
and a specificity value of 84.6% (AUC¼0.798, P¼ 0.025, 95%
confidence interval: 0.594–1.000, Figure 5A). In subsequent
logistic regression analysis, SUVmax>4.5 was found to infer a
16-fold greater risk for loss of SMAD4 in resected left-sided
pancreatic cancer (Exp[b]¼16.5, P¼ 0.012, 95% confidence
interval: 1.832–148.606).
Prediction of Initial Recurrence as Systemic
Metastasis
SUVmax>4.5 predicted early cancer recurrence in resected
left-side pancreatic cancer (mean 63.9 months [95% CI: 46.0–
81.7] vs 11.5 months [95% CI: 5.9–17.1], P< 0.001,
SUVmax Value Detecting SMAD4 Loss in PDACFigure 5B). In particular, resected pancreatic cancers without
SMAD4 expression showed earlier systemic metastasis, com-
pared to those with intact SMAD4 expression (22.3 months
4 Expression in Resected Left-Sided Pancreatic Cancer
SMAD4 Expression
st SMAD4 Intact SMAD4 P-Value
2/8 11/11 0.141
2.6 10.3 63.3 9.2 0.889
3/7 13/9 0.126
8/2 12/10 0.163
3.6 297.9 186.2 243.0 0.087
3.7 1.8 3.1 1.3 0.388
7/3 20/2 0.162
//10/ /2/18/2 0.572
3/7 11/11 0.446
.15 0.15 0.33 1.23 0.635
2/5/2/1/ 5/16/1/- 0.171
4/5 14/6 0.237
2/7 12/8 0.268
8/2/- 19/1/2 0.299
derate differentiation; NS¼P > 0.1; PD¼ poorly differentiation;
ion.
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FIGURE 3. Disease-free survival according to SMAD4 expression
in resected left-sided pancreatic cancer. According to SMAD4
expression, a significant difference in disease-free survival was
noted in resected left-sided pancreatic cancer (mean 57.4 months
[95% CI: 41.4–73.3] vs mean 17.6 months [95% CI: 6.3–28.9],
Kang et al[95% CI: 8.9–35.7] vs 62.5 months [95% CI: 46.7–78.3],
P¼ 0.022) (Figure 6A). In addition, resected pancreatic cancers
with a SUVmax >4.5 were also associated with early systemic
metastasis (14.3 months [95% CI: 8.0–20.5] vs 66.1 months
P¼0.006). CI¼ confidence interval.[95% CI: 47.3–84.8], P< 0.001) (Figure 6B). In Cox’s pro-
portional hazards model, both loss of SMAD4 expression (Exp
[b] ¼ 4.620, P¼ 0.039) and SUVmax >4.5 (Exp [b] ¼ 11.650,
FIGURE 4. Signal intensities of FDG-uptake according to SMAD4 expr
scan is related to SMAD4 expression in resected left-sided pancreat
represent intact SMAD4 expression (B), whereas high-signal inten
FDG¼fluoro-deoxyglucose, PET-CT¼positron emission tomography-
4 | www.md-journal.comP¼ 0.003) were independent prognostic factors for predicting
early systemic metastasis.
DISCUSSION
Although SMAD4 expression is potentially involved in
pancreatic cancer, a relationship between loss of or reduced
SMAD4 expression and poor oncologic outcomes has not been
consistently observed. Smith et al16 performed a meta-analysis
of immunohistochemical prognostic markers in resected pan-
creatic cancer. Therein, loss of SMAD4 expression was noted in
a median of 25% of patients (range, 24–85% of 540 patients),
with no significant overall association between SMAD4 expres-
sion and survival from resected pancreatic cancer. Studies
reporting no oncologic significance for SMAD4 in pancreatic
cancer mostly involved patients with pancreatic head cancer and
only a small proportion of patients with body/tail cancer:Winter
et al10 studied 110 patients with pancreatic head cancer and 15
patients with left-sided pancreatic cancer. This suggests the
possibility of contamination by other periampullary cancers,
such as cancers of the bile duct, ampulla of Vater, or duodenum.
In periampullary cancers, the exact origin of a cancer is often
unclear. Therefore, our study focused on resected left-sided
pancreatic cancer in order to minimize issues related to patho-
logical contamination and to provide information about clinical
applications for resectable pancreatic cancer.
The present results clearly demonstrated that loss of
SMAD4 expression has a significant adverse oncologic impact
on resected left-sided pancreatic cancer (Figure 3). In addition,
a potential correlation between SMAD4 expression and
SUV was an important observation (Figure 4 and
Medicine  Volume 95, Number 17, April 2016max
Table 2). Multivariate analysis showed that mean SUVmax >
4.3 is an independent predictive factor for determining loss of
SMAD expression (Exp[b] ¼ 10.0, P¼ 0.028).
ession. The signal intensity of FDG-uptake in preoperative PET-CT
ic cancer. Low-signal intensity in FDG-PET-CT (A) was found to
sity of FDG uptake (C) reflected no SMAD4 expression (D).
computed tomography.
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TABLE 2. Differences in PET-Based Parameters According to
SMAD4 Expression in Resected Left-Sided Pancreatic Cancer
SMAD4 Expression
Lost SMAD4 Intact SMAD4 P-value
SUVmax 5.4 2.2 3.6 1.7 0.025
MTV2.5 5.9 4.8 2.8 2.1 0.445
TLG2.5 24.9 23.5 10.5 13.4 0.268
MTVEdge 7.5 7.6 4.3 3.5 0.295
TLGEege 27.631.8 12.013.5 0.185
Medicine  Volume 95, Number 17, April 2016Several studies have suggested potential clinical appli-
cations for SMAD4 expression in treatment of pancreatic
cancer. Oshima et al17 reported that immunohistochemically
detected SMAD4 expression strongly predicts oncologic out-
comes for resected pancreatic cancer. They showed that loss of
SMAD4 immunolabeling is an independent and significant
MTV¼metabolic tumor volume; SUVmax,¼maximum standardized
uptake; TLG¼ total lesion glycolysisprognostic factor for poor overall and disease-free survival.
Crane et al18 demonstrated chemotherapeutic agent effective-
ness according to SMAD4 immunostaining of locally advanced
FIGURE 6. Systemic metastasis-free survival according to SMAD4 exp
earlier systemicmetastasis in resected left-sided pancreatic cancer (22.3
P¼0.022) (A), and SUVmax>4.5 was also related to early systemic met
47.3–84.8], P<0.001) (B). CI¼ confidence interval, SUVmax¼maxim
FIGURE 5. Optimal cut-off value for SUVmax to predict loss of SMAD4
predictive of tumor recurrence with a sensitivity of 75% and specific
SUVmax¼4.5 discriminated disease-free survival (mean 63.9months [9
(B). CI¼ confidence interval, ROC¼ receiver operating characteristic,
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.pancreatic cancer, showing that SMAD4 expression is corre-
lated with local, rather than distant, dominant patterns of
disease progression.
In clinical situations, preoperative SMAD4 expression in
resectable pancreatic cancer can be determined by endoscopic
ultrasound (EUS)-guided fine needle aspiration biopsy (FNAB).
Although extensive gastroenterologist experience increases the
safety and high diagnostic performance of EUS-guided
FNAB,19 the following disadvantages of EUS-guided FNAB
should be considered: (1) the procedure is invasive and
operator-dependent. (2) Immunostaining for targeted protein,
such as SMAD4, takes time. (3) Rebiopsy is often recom-
mended because of insufficient tissue material.
Meanwhile, PET/PET-CT is noninvasive and provides
useful information on diagnosis, staging, and biological beha-
vior for treating pancreatic cancer in preoperative settings.20
Several studies have shown the oncological significance of
preoperative PET/PET-CT in resected pancreatic can-
cer.12,13,21,22 According to our results, loss of SMAD4 expres-
sion is associated with increases in PET-based parameters
(Table 2). In particular, SUVmax> 4.5 predicted loss of SMAD4
expression with 75% sensitivity and a 15.4% false-positive
rate (Figure 5A). More importantly, oncologic outcomes were
SUVmax Value Detecting SMAD4 Loss in PDACclearly differentiated by a SUVmax cut-off of 4.5 (Figure 5B), as
shown in survival differences according to SMAD4 expression
(Figure 3). In addition, both loss of SMAD4 expression
ression and SUVmax value, 4.5. Loss of SMAD4 was associated with
months [95%CI: 8.9–35.7] vs 62.5months [95%CI: 46.7–78.3],
astasis (14.3 months [95% CI: 8.0–20.5] vs 66.1 months [95% CI:
um standardized uptake.
and recurrence. In ROC analysis, a SUVmax of 4.5 was found to be
ity of 84.6% (A). Subsequent survival analysis demonstrated that
5%CI: 46.0–81.7] vs 11.5months [95%CI: 5.9–17.1], P<0.001)
SUVmax¼maximum standardized uptake.
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(Exp [b] ¼ 4.620, P¼ 0.039) and SUVmax > 4.5 (Exp [b] ¼
11.650, P¼ 0.003) were independent predictive factors of early
systemic metastasis.
This study was retrospective in design and included a small
study population. Therefore, selection bias could not be
avoided. However, to the best of our knowledge, this study
is the first to correlate SMAD4 expression and tumor metab-
olism (PET-based parameters) in resected pancreatic cancer.
The potential correlations between SMAD4 expression and
PET-based parameters suggest a patient-oriented surgical
approach to treating resectable pancreatic cancer. Despite some
debate, the literature shows that loss of SMAD4 is associated
with dissemination of pancreatic cancer cells. If PET-based
parameters, such as SUVmax, are indeed found to be of use as
representative clinical biomarkers for SMAD4 expression and
early systemic recurrence, then alternative surgical strategies
(e.g., neoadjuvant treatment followed by pancreatectomy) could
be recommended according to SUVmax values, even for resect-
able pancreatic cancers. The validity of such approaches should
first be explored in a larger number of patients.
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